BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors. “What we are doing...
BC Extra | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

Novartis is pivoting away from internal development of CAR Ts in solid tumors, it said Thursday at its R&D day. The company is, however, pressing forward with the modality via partnerships, and plans to use...
BC Week In Review | Aug 31, 2018
Clinical News

SAB's SAB-139 protects non-human primates from Ebola virus infection

SAB Biotherapeutics Inc. (Sioux Falls, S.D.) reported data from 12 rhesus macaques challenged with a lethal dose of Ebola virus showing that SAB-139 given one or three days postinfection conferred 100% protection against Ebola virus...
BioCentury | Aug 4, 2018

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
BC Innovations | Jul 27, 2017
Translation in Brief

Cycling across the membrane

In a Nature Chemistry study, a German team has shown that nanobodies coupled to cyclic peptides rich in arginine can target intracellular proteins with antibody-like precision and even deliver extracellular proteins to the cytosol. Delivering...
BioCentury | Jan 6, 2017
Emerging Company Profile

Gobbling globulins

Syntimmune Inc. is targeting a receptor that mediates the life span and activity of immunoglobulin G to control autoimmune disease more precisely and potentially more safely than broadly acting agents. The company aims to differentiate...
BC Week In Review | Dec 30, 2016
Company News

Harbour BioMed, Harbour Antibodies deal

Harbour BioMed acquired Harbour Antibodies for an undisclosed upfront payment and equity investment. Harbour Antibodies’ H2L2 transgenic mouse platform generates human IgG mAbs with two heavy chain and two light chain immunoglobulins, and its HCAb...
BC Week In Review | Dec 1, 2016
Clinical News

Blisibimod: Ph III CHABLIS-SC1 data

Top-line data from the double-blind, international Phase III CHABLIS-SC1 trial in about 442 patients with SLE despite ongoing stable corticosteroid therapy showed that once-weekly subcutaneous blisibimod missed the primary endpoint of a greater proportion of...
BC Week In Review | Apr 4, 2016
Company News

Quest Pharma, Shenzhen Hepalink Pharmaceutical deal

Quest’s OncoQuest Inc. subsidiary and Hepalink formed newco OncoVent Co. Ltd. to develop immunotherapies for cancer in China. Hepalink will own 54% of OncoVent’s shares, and Quest PharmaTech and OncoQuest will own 46%. The partners...
BioCentury | Dec 7, 2015

Action in amyloidosis

The Amyloidosis Research Consortium is following in the footsteps of another well-organized rare disease community by drafting a proposed FDA guidance that will reflect patients' priorities. The advocacy group also plans to qualify a cardiac...
Items per page:
1 - 10 of 94